Packer (21) has summarized that SGLT2-inhibitors could protect HF both from activating the Sirt1/PGC1α/FGF21 signaling transition and directly upregulating the expression of Sirt1, PGC1α, and FGF21. The gene discussed is SIRT1; the disease is hydrops fetalis.